High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3571-3578

  Pica, Francesca ^a   Fraschetti, Marzia ^a   Matteucci, Claudia ^a   Tuthill, Cynthia ^b   Rasi, Guido ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SciClone Pharmaceuticals Inc   (United States)

^c CNR   (Italy)

Author keywords

B16 melanoma; Chemoimmunotherapy; CTL; Cyclophosphamide; Interferon alpha beta; Mouse; Murine; NK cell; Thymosin alpha 1

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR; THYMOSIN ALPHA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-BETA; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE SUBSETS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SPLEEN; THYMOSIN;

EID: 0031762984     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL and Garaci E: Synergistic effect of thymosin al and αβ-interferon on NK activity in tumor bearing mice. Int J Immunopharmac 11: 443-450, 1989.
2. Gold JE, Zachary DT, Osband ME: Adoptive transfer of ex vivo-activated memory T cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic muri melanoma. Int J Cancer 61: 580-586, 1995.
3. LoRusso PM, Aukerman SL, Polin L, Redman BG, Valdivieso M, Biernat L, Corbett TH: Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumo systems. Cancer Res 50: 5876-5882, 1990.
4. Kaido T, Bandu MT, Maury C, Ferrantini M, Belardelli and Gresser I: IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 60: 221-229, 1995.
5. Garaci E, Mastino A, Favalli C: Enhanced immune response and antitumor immunity with combinations biological response modifiers. Bull NY Acad Med 65: 111-119, 1989.
6. Goldstein AL, Guha A, Zatz MM, Hardy M, and White A: Purification and biological activity of thymos a hormone of the thymus gland. Proc Nat Acad Sci 69: 1800-1803, 1972.
7. Stzein MB, Serrate SA: Characterization of the immunoregulatory properties of thymosin alpha 1 interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol 11: 789-800, 1989.
8. Favalli C, Jezzi T, Mastino A, Rinaldi -Garaci C, Riccardi C and Garaci E: Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 20: 189-192, 1985.
9. Garaci E, Mastino A, Pica F, and Favalli C: Combination treatment using thymosin al and interferon af cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother 32: 154-160, 1990.
10. Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, and Garaci E: Combination therapy with thymosin α1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment the Lewis lung carcinoma in mice. Int J Cancer, 50: 493-499, 1992.
11. Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C: Antitumor effect of thymosin al/Interleukin-2 or thymosin α1/Interferon α/β following cyclophosphamide in mice injected with higl metastatic Friend leukemia cells. J Immunother 13: 7-17, 1993.
12. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, and GE: Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouraci liver metastases from colorectal cancer in rats. Int J Cancer 57: 701-705, 1994.
13. Herberman RB, Nunn ME, and Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells agair syngeneic and allogeneic tumors. I. Distribution of Reactivity. Int J Cancer 16: 216-222, 1975.
14. Tanaka T, Tsudo M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M, Taniguchi T, Miyasaka M novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expre in normal lymphoid cells and EL4 cells. J Immunol 147: 2222-2228, 1991.
15. Nakanishi K, Hirose S, Yoshimoto T, Ishizashi H, Hiroishi K, Tanaka T, Kono T, Miyasaka M, Taniguchi T, Higashino K: Role and regulation of interleukin (IL)-2 receptor alpha and beta chains in driven B-cell growth. Proc Natl Acad Sci USA 89: 3551-3555, 1992.
16. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C, Rasi G, Santini S, Capomc E, Vici P, and Di Lauro L: Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-al and interferon-a2a. Eur J Cancer 31A: 2403-2405, 1995.
17. Salvati F, Rasi G, Portalone L, Antilli A, and Garaci E: Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-11 controlled trial. Anticancer Res 16: 1001-1004, 1996.
18. Lopez M, Carpano S, Cavaliere R, Di Lauro L, Ameglio F, Vitelli G, Frasca AM, Vici P, Pignatti F, Rosselli M, Rasi G, and Garaci E: Biochemotherapy with thymosin al, interleukin-2 and dacarbazine patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 5: 741-746, 1994.
19. Garaci E, Pica F, Rasi G, Palamara AT, Favalli C: Combination therapy with BRMs in cancer and infectious, diseases. Mech Ageing Dev 96: 103-116, 1997.
20. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK: The interferons. Mechanisms of action and clinical applications. JAMA 266: 1375-1383, 1991.
21. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents ag. experimental and human malignancies: a review. Cancer Res 50: 3473-3486, 1990.
22. Moody TW, Fagarasan M, Zia F, Cesnjaj M and Goldstein AL: Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 53: 5214-5218, 1993
23. Haung KJY, Kind PD, Jagoda EM, Goldstein AL: Thymosin treatment modulates productions of interferon. J Int Res 1: 411, 1981.
24. Shoham J, Eshel I, Aboud M, Salzberg S: Thymic hormonal activity on human perpheral blood lymphocytes, in vitro. II. Enhancement of the production of immune interferon by activated cells. J Immunol 125: 54, 1980.
25. Svederrsky LP, Hui A, May L, McKay P, and Stebbing N: Induction and augmentation of mitogen- induced immune interferon production in human peripheral blood lymphocytes by a-desacetyl thymosin α1. Eur J Immunol 12: 244-247, 1982.
26. Kouttab NM, Goldstein AL, Lu M, Campbell B, and Maizel AL: Production of human B and T cell gro factor is enhanced by thymic hormones. Immunopharmacology 16: 97-105, 1988.
27. Thurman GB, Seals C, Low TLK, and Goldstein AL: Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by peripheral blood lymphocytes of adult thymectomized guinea pigs. J Biol Resp Mod 3: 160-173, 1984.
28. Otha Y, Sueki K, Kitta K, Takemoto K, Ishitsuk H, and Yagi Y: Comparative studies on the immunosuppressive effect among 5-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann 71: 190-196, 1980.
29. Otha Y, Tezuka E, Tamura S, and Yagi Y: Thymosin alpha 1 exerts protective effect against the 5-FU induced bone-marrow toxicity. Int J Immunopharmac 7: 761-768 1985.
30. Allavena P, Giardina G, Sen S, Colella G, Broggini M, D'Incalci M: IFN-beta partially counteract inhibition of natural killer activity induced by some anti-tumor agents. J Interferon Cytokine Res 18: 87-93, 1998.